Moderna vs Vertex Pharmaceuticals — CEO Pay Comparison
Reshma Kewalramani (Vertex Pharmaceuticals) earns $2.3M more in total compensation than Stephane Bancel (Moderna).
| Metric | ModernaMRNA | Vertex PharmaceuticalsVRTX |
|---|---|---|
| CEO | Stephane Bancel | Reshma Kewalramani |
| Industry | Biotechnology | Biotechnology |
| Total Compensation | $9.7M | $12.0M |
| Base Salary | $966K | $1.2M |
| Stock Awards | $4.8M | $6.0M |
| Option Awards | $1.2M | $1.4M |
| Non-Equity Incentive | $1.4M | $1.8M |
| Pay-for-Performance Grade | A (96/100) | A (100/100) |
| CEO-Worker Pay Ratio | 77:1 | 96:1 |
| Median Worker Pay | $125K | $125K |
| Say-on-Pay Approval | 85.6% | 95.8% |
| 3yr Total Shareholder Return | +584.1% | +88.7% |
| Revenue | $6.7B | $10.3B |
| Market Cap | $35.0B | $120.0B |
| Employees | 5,700 | 10,400 |
Analysis
Stephane Bancel (Moderna) earns $9.7M in total compensation, while Reshma Kewalramani (Vertex Pharmaceuticals) earns $12.0M. That is a difference of $2.3M.
On pay-for-performance alignment, Moderna scores A (96/100) while Vertex Pharmaceuticals scores A (100/100). Vertex Pharmaceuticals's CEO compensation is better aligned with company performance.
Moderna's CEO-to-worker pay ratio is 77:1 compared to Vertex Pharmaceuticals's 96:1. Shareholders approved CEO pay at 85.6% (Moderna) and 95.8% (Vertex Pharmaceuticals).